2 terminated, 1 completed, 1 unknown. 1 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Guanabenz: new trials by email Literature Review of Guanabenz trials Research Report on Guanabenz
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease Experimental: 4 mg/day of WY-8678 (guanabenz acetate), Experimental: 8 mg/day of WY-8678 (guanabenz acetate) - Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | Phase 2 | Unknown | Yokohama City University | 29 | 2021-10-29 | 2022-09-27 |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis Guanabenz acetate - Bone Cancer, Metastasis | Not applicable | Terminated | Kathy Miller | 4 | 2015-05-07 | 2018-02-13 |
| Oral Guanabenz for Multiple Sclerosis Guanabenz - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis | Phase 1 | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | 2 | 2015-04-21 | 2019-12-12 |
Bone Neoplasms (1) · Hypertension (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Neoplasm Metastasis (1) · Non-alcoholic Fatty Liver Disease (1)
Kathy Miller (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · University of Utah (1) · Yokohama City University (1)
United States (3) · Japan (1)
Adam P Bress, PharmD, MS (1) · Irene CM Cortese, M.D. (1) · Kathy Miller, MD (1)